Patents Assigned to Amgen
  • Modified peptides as therapeutic agents
    Publication number: 20040057953
    Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides.
    Type: Application
    Filed: August 29, 2003
    Publication date: March 25, 2004
    Applicant: Amgen Inc.
    Inventors: Ulrich Feige, Chuan-Fa Liu, Janet C. Cheetham, Thomas Charles Boone
  • Modified peptides as therapeutic agents
    Publication number: 20040053845
    Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides.
    Type: Application
    Filed: July 31, 2003
    Publication date: March 18, 2004
    Applicant: Amgen Inc.
    Inventors: Ulrich Feige, Chuan-Fa Liu, Janet C. Cheetham, Thomas Charles Boone
  • Human E3&agr; ubiquitin ligase family
    Patent number: 6706505
    Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3&agr; ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: March 16, 2004
    Assignee: Amgen Inc
    Inventors: Hui-Quan Han, Keith Kwak
  • Combination therapy using a TNF binding protein for treating TNF-mediated diseases
    Publication number: 20040048799
    Abstract: The invention relates to methods for treating or preventing acute and/or chronic arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and methotrexate (N-[4-[[2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid). In a preferred embodiment, the TNF binding protein is sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and methotrexate useful in such methods.
    Type: Application
    Filed: July 16, 2003
    Publication date: March 11, 2004
    Applicant: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello, Carl K. Edwards
  • Combination therapy using a TNF binding protein for treating TNF-mediated diseases
    Publication number: 20040047863
    Abstract: The invention relates to methods for treating or preventing acute and/or chronic arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and methotrexate (N-[4-[[2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid). In a-preferred embodiment, the TNF binding protein is sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and methotrexate useful in such methods.
    Type: Application
    Filed: July 16, 2003
    Publication date: March 11, 2004
    Applicant: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello, Carl K. Edwards
  • Use of II-1 inhibitors for treating II-1 mediated diseases
    Publication number: 20040044001
    Abstract: The invention relates to methods for treating or preventing arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and methotrexate. In a preferred embodiment, the IL-1 inhibitor is human recombinant IL-1ra and the methotrexate is N-[4-[(2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid. The invention also relates to pharmaceutical compositions containing an IL-1 inhibitor and methotrexate useful in such methods.
    Type: Application
    Filed: July 16, 2003
    Publication date: March 4, 2004
    Applicant: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello
  • Modified peptides as therapeutic agents
    Publication number: 20040044188
    Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides.
    Type: Application
    Filed: June 27, 2003
    Publication date: March 4, 2004
    Applicant: Amgen Inc.
    Inventors: Ulrich Feige, Chuan-Fa Liu, Janet C. Cheetham, Thomas Charles Boone
  • Thiazolyl urea compounds and methods of uses
    Publication number: 20040044044
    Abstract: Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: July 30, 2003
    Publication date: March 4, 2004
    Applicant: Amgen Inc.
    Inventors: Benny C. Askew, Frenel F. De Morin, Andrew Hague, Ellen Laber, Aiwen Li, Gang Liu, Patricia Lopez, Rana Nomak, Vincent Santora, Christopher Tegley, Kevin Yang
  • Thiazolyl urea compounds and methods of uses
    Publication number: 20040039029
    Abstract: Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: July 30, 2003
    Publication date: February 26, 2004
    Applicant: Amgen Inc.
    Inventors: Benny C. Askew, Frenel F. De Morin, Andrew Hague, Ellen Laber, Aiwen Li, Gang Liu, Patricia Lopez, Rana Nomak, Vincent Santora, Christopher Tegley, Kevin Yang
  • Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
    Publication number: 20040029863
    Abstract: Selected novel carboxylic acid substituted heterocycle compounds are effective for prophylaxis and treatment of inflammation, tissue degradation, cancer, fibrosis and related diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of inflamation, tissue degradation and related diseases. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: June 23, 2003
    Publication date: February 12, 2004
    Applicant: Amgen Inc.
    Inventors: Kevin Koch, Andreas Termin, John A. Josey
  • Use of GM-CSF to promote accelerated wound healing
    Patent number: 6689351
    Abstract: A method utilizing GM-CSF to promote accelerated wound healing in mammals is described. This method comprises administering topically to the mammal a therapeutically effective amount of this polypeptide. In addition, such methods comprising admixtures containing GM-CSF and at least one other protein are also disclosed.
    Type: Grant
    Filed: September 13, 1994
    Date of Patent: February 10, 2004
    Assignee: Amgen Inc.
    Inventors: Glenn Pierce, Bruce W. Altrock
  • Kinase inhibitors
    Publication number: 20040019067
    Abstract: The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.
    Type: Application
    Filed: October 22, 2002
    Publication date: January 29, 2004
    Applicant: Amgen Inc.
    Inventors: David M. Armistead, Jean E. Bemis, Daniel Elbaum, Gregory J. Habgood, Perry M. Novak, Joseph J. Nunes, Leticia M. Toledo-Sherman
  • Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
    Patent number: 6683155
    Abstract: The present invention reveals a class of novel inhibitors of metalloproteinase. For convenience, these polypeptides are referred to as “TIMP-3”, as these polypeptides represent a new class of members of the tissue inhibitors of metalloproteinases. Also provided are DNA sequences coding for all or part of the TIMP-3s, vectors containing such DNA sequences, and host cells transformed or transfected with such vectors. In addition, methods of producing recombinant TIMP-3s, methods of treating disorders, pharmaceutical compositions including TIMP-3s and antibodies selectively binding TIMP-3s are provided.
    Type: Grant
    Filed: October 9, 1996
    Date of Patent: January 27, 2004
    Assignee: Amgen Inc.
    Inventors: Scott M. Silbiger, Raymond A. Koski
  • Glucagon antagonists
    Patent number: 6677136
    Abstract: The present invention concerns therapeutic agents that antagonize the activity of glucagon. In accordance with the present invention, the compounds of the invention comprise: a. a glucagon antagonist domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques; and b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the glucagon antagonist domain. The vehicle and the glucagon antagonist domain may be linked through the N- or C-terminus of the glucagon antagonist domain. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: January 13, 2004
    Assignee: Amgen Inc.
    Inventors: William S. Marshall, Kevin Lee Stark
  • Mammalian cell cycle protein
    Patent number: 6673903
    Abstract: A novel mammalian cell cycle protein, p55CDC, DNA sequences encoding p55CDC, and a method for producing the protein are described. Also described are methods for detecting p55CDC and methods for modulating cell division by compounds which control the level or activity of p55CDC or p55CDC-associated protein complexes.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: January 6, 2004
    Assignees: Amgen Inc., The Regents of the University of California
    Inventor: Jasminder Weinstein
  • Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
    Publication number: 20030236196
    Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.
    Type: Application
    Filed: June 12, 2003
    Publication date: December 25, 2003
    Applicant: Amgen Inc.
    Inventors: Bruce Kerwin, Byeong Chang, Lei Shi
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Publication number: 20030236193
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: April 9, 2003
    Publication date: December 25, 2003
    Applicant: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Her-2 receptor tyrosine kinase molecules and uses thereof
    Publication number: 20030228606
    Abstract: The present invention provides HER-2 Receptor Tyrosine Kinase polypeptides and nucleic acid molecules encoding the same. Specifically, the present invention relates to splice variants of HER-2 (HER-2sv). The invention also provides selective binding agents, vectors, host cells, and methods for producing HER-2sv polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with HER-2sv polypeptides.
    Type: Application
    Filed: April 11, 2003
    Publication date: December 11, 2003
    Applicant: Amgen Inc., A Corporation of the State of Delaware
    Inventors: Suzanna Tatarewicz, Shuqian Jing
  • Modified peptides as therapeutic agents
    Patent number: 6660843
    Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: December 9, 2003
    Assignee: Amgen Inc.
    Inventors: Ulrich Feige, Chuan-Fa Liu
  • Substituted alkylamine derivatives and methods of use
    Publication number: 20030225106
    Abstract: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: July 17, 2002
    Publication date: December 4, 2003
    Applicant: Amgen Inc.
    Inventors: Benny Askew, Jeffrey Adams, Shon Booker, Guoqing Chen, Lucian V. DiPietro, Daniel Elbaum, Julie Germain, Stephanie D. Geuns-Meyer, Gregory J. Habgood, Michael Handley, Qi Huang, Tae-Seong Kim, Aiwen Li, Nobuko Nishimura, Rana Nomak, Vinod F. Patel, Babak Riahi, Joseph L. Kim, Ning Xi, Kevin Yang, Chester Chenguang Yuan